Alisertib

Drug Profile

Alisertib

Alternative Names: Alsertib; Aurora A inhibitor; MLN-8237

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Fox Chase Cancer Center; Massachusetts General Hospital; Mayo Clinic; Millennium; National Cancer Institute (USA); Ohio State University Comprehensive Cancer Center; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College; Yale University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Benzazepines; Benzoic acids; Fluorobenzenes; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; B cell lymphoma; Brain cancer; Breast cancer; Mesothelioma; Prostate cancer; Small cell lung cancer
  • Phase I/II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Burkitt's lymphoma; Cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Lymphoma; Non-Hodgkin's lymphoma; Oesophageal cancer
  • Preclinical Head and neck cancer
  • Discontinued Myelodysplastic syndromes; Ovarian cancer; Peripheral T-cell lymphoma

Most Recent Events

  • 06 Jul 2017 Phase-II clinical trials in Breast cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO) (NCT02860000)
  • 06 Jul 2017 Phase-II clinical trials in Breast cancer (Late-stage disease, Inoperable/Unresectable, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02860000)
  • 30 Jun 2017 Washington University School of Medicine completes enrolment in a phase I trial for Solid tumour (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT01677559)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top